Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
44.76
+3.39 (8.19%)
Jun 5, 2025, 12:20 PM - Market open
PRAX Employees
Praxis Precision Medicines had 116 employees as of December 31, 2024. The number of employees increased by 34 or 41.46% compared to the previous year.
Employees
116
Change (1Y)
34
Growth (1Y)
41.46%
Revenue / Employee
$70,017
Profits / Employee
-$1,832,431
Market Cap
911.72M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 116 | 34 | 41.46% |
Dec 31, 2023 | 82 | -27 | -24.77% |
Dec 31, 2022 | 109 | -30 | -21.58% |
Dec 31, 2021 | 139 | 72 | 107.46% |
Dec 31, 2020 | 67 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
PRAX News
- 19 hours ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga
- 4 weeks ago - Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Participate in Upcoming April Conferences - GlobeNewsWire
- 3 months ago - Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
- 3 months ago - Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewsWire
- 4 months ago - Praxis Precision Medicines to Present at Two February Investor Conferences - GlobeNewsWire